Immunovant
IMVT
32.04
-0.07
-0.22%
Immunovant
US · IMVT
#1790 by market cap
Listed 2017
32.04
-0.07
-0.22%
Live - 5344 symbols - heartbeat 413s ago
· 2026-10-08 07:11
Pre-market
31.00
-3.25%
After-hours
32.04
0.00%
Overnight
30.98
-3.31%
- Market cap
- 6.62B
- P/E (TTM)i
- -11.40
- P/Bi
- 9.00
- EPSi
- -2.77
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on IMVT?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 18.15M | 39.51M | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Research & development | -- | 47.93M | 68.60M | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Operating profit | -- | -66.08M | -108.12M | -156.03M | -208.28M | -270.21M | -438.15M | -532.90M |
| Pretax profit | -- | -66.29M | -107.79M | -156.81M | -210.95M | -258.77M | -412.95M | -505.39M |
| Tax | -- | 97.00K | -358.00K | -84.00K | 9.00K | 567.00K | 891.00K | 215.00K |
| Net profit | -- | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M | -413.84M | -505.61M |
| Basic EPS | -- | -2 | -1 | -1 | -2 | -2 | -3 | -3 |
| Diluted EPS | -- | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 20.17M | 26.02M | 17.51M | 15.44M | 17.27M | 17.69M |
| Research & development | 93.65M | 101.20M | 114.25M | 98.92M | 142.29M | 142.63M |
| Operating profit | -113.83M | -127.22M | -131.76M | -114.36M | -159.55M | -160.32M |
| Pretax profit | -105.87M | -119.70M | -125.91M | -109.08M | -150.70M | -153.22M |
| Tax | 583.00K | 913.00K | 594.00K | 1.55M | -2.84M | 0 |
| Net profit | -106.45M | -120.61M | -126.50M | -110.64M | -147.86M | -153.22M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.64 | -0.71 | -0.73 | -0.61 | -0.73 | -0.75 |
Balance sheet
| Line item | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 325.00K | 109.08M | 409.01M | 512.93M | 404.33M | 665.77M | 767.66M | 948.82M |
| Cash & ST investments | 325.00K | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 405.00K | 109.39M | 412.49M | 515.56M | 405.84M | 666.37M | 776.22M | 957.01M |
| Total current liabilities | 380.45K | 15.32M | 18.77M | 44.52M | 43.30M | 48.61M | 68.78M | 104.42M |
| Short-term debt | 300.00K | -- | 1.18M | 1.15M | 1.17M | 138.00K | 98.00K | 72.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 380,448.00 | 15,318,000.00 | 21,009,000.00 | 45,739,000.00 | 43,344,000.00 | 48,608,000.00 | 68,775,000.00 | 104,422,000.00 |
| Total equity | 24.55K | 94.07M | 391.48M | 469.83M | 362.49M | 617.76M | 707.45M | 852.59M |
| Retained earnings | -448 | -91.23M | -198.66M | -355.39M | -566.35M | -825.68M | -1.24B | -1.75B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 767.66M | 651.76M | 573.55M | 1.04B | 948.82M | 851.18M |
| Cash & ST investments | 713.97M | 598.91M | 521.87M | 994.53M | 902.11M | 797.80M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 776.22M | 661.44M | 582.96M | 1.05B | 957.01M | 852.49M |
| Total current liabilities | 68.78M | 52.90M | 63.25M | 66.26M | 104.42M | 117.10M |
| Short-term debt | 98.00K | -- | -- | -- | 72.00K | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 68,775,000.00 | 52,900,000.00 | 63,254,000.00 | 66,257,000.00 | 104,422,000.00 | 117,102,000.00 |
| Total equity | 707.45M | 608.54M | 519.71M | 986.14M | 852.59M | 735.39M |
| Retained earnings | -1.24B | -1.36B | -1.49B | -1.60B | -1.75B | -1.90B |
Cash flow
| Line item | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -53.36M | -83.33M | -106.11M | -188.19M | -214.23M | -375.87M | -407.31M |
| Depreciation & amortization | -- | 21.00K | 65.00K | 126.00K | 193.00K | 231.00K | 377.00K | 409.00K |
| Free cash flow | -- | -53.39M | -83.54M | -106.37M | -188.39M | -214.59M | -376.63M | -407.32M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 319.78M | 0 | 70.50M | 472.75M | 450.00M | 544.19M |
| Ending cash balance | -- | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -110.64M | -117.41M | -102.52M | -92.33M | -95.06M | -124.41M |
| Depreciation & amortization | 109.00K | 107.00K | 105.00K | 101.00K | 96.00K | 92.00K |
| Free cash flow | -110.84M | -117.41M | -102.52M | -92.33M | -95.07M | -124.41M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 450.00M | -- | -- | -- | 0 | -- |
| Ending cash balance | 713.97M | 598.91M | 521.87M | 994.53M | 902.11M | 797.80M |
Returns & efficiency
| Line item | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -141.11 | -44.25 | -36.39 | -50.69 | -52.91 | -62.46 | -64.82 |
| ROA %i | -- | -121.02 | -41.17 | -33.78 | -45.79 | -48.37 | -57.37 | -58.34 |
| ROIC %i | -- | -140.14 | -43.64 | -36.15 | -52.29 | -56.85 | -65.39 | -66.76 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -65.07 | -49.34 | -53.45 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.85 | 7.12 | 21.79 | 11.52 | 9.34 | 13.70 | 11.16 | 9.09 |
| Quick ratioi | 0.85 | 6.76 | 21.38 | 11.38 | 8.72 | 13.18 | 10.42 | 8.68 |
| Debt / assetsi | 74.07 | 0.00 | 0.83 | 0.46 | 0.30 | 0.02 | 0.01 | 0.01 |
| LT debt / equityi | -- | -- | 0.57 | 0.26 | 0.01 | -- | -- | -- |
| Interest coveragei | -- | -105.07 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -62.46 | -77.58 | -95.93 | -69.35 | -64.82 | -80.10 |
| ROA %i | -57.37 | -71.50 | -84.59 | -63.01 | -58.34 | -71.10 |
| ROIC %i | -65.39 | -80.85 | -99.75 | -72.20 | -66.76 | -83.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.16 | 12.32 | 9.07 | 15.74 | 9.09 | 7.27 |
| Quick ratioi | 10.42 | 11.36 | 8.28 | 15.03 | 8.68 | 6.82 |
| Debt / assetsi | 0.01 | -- | -- | -- | 0.01 | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:11:09 · For reference only, not investment advice and not tailored to your situation.